JUPITER NEUROSCIENCES, INC.
JUNSDrugs in Pipeline
2
Phase 3 Programs
0
Upcoming Catalysts
1
Next Catalyst
Next month
Market Overview
Stock performance and key metrics
1 upcoming, 0 past
How JUNS's past catalysts played out
Trans-Resveratrol
Parkinson's Disease
Oxygen at 1.5 ATA (atmospheres absolute).
Traumatic Brain Injury
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
Trans-Resveratrol | Phase 2 | Parkinson's Disease | - | - |
Oxygen at 1.5 ATA (atmospheres absolute). | Phase 2 | Traumatic Brain Injury | - | - |
Full breakdown — the signals behind the verdict
Frequently asked questions
What is in JUPITER NEUROSCIENCES, INC.'s drug pipeline?→
CatalystAlert tracks 2 drug candidates in JUPITER NEUROSCIENCES, INC.'s (JUNS) pipeline across Phase 2. Its lead program is Trans-Resveratrol (Phase 2). Each drug's phase, indication and upcoming catalysts are listed on this page.
When is JUPITER NEUROSCIENCES, INC.'s next FDA catalyst?→
JUPITER NEUROSCIENCES, INC.'s (JUNS) next tracked catalyst is a Earnings expected November 13, 2026. See the catalyst timeline on this page for the full schedule of PDUFA dates, trial readouts and FDA events.
How do I track JUNS biotech catalysts?→
Add JUNS to your CatalystAlert watchlist for alerts ahead of each catalyst, and follow JUPITER NEUROSCIENCES, INC.'s live catalyst calendar, drug pipeline and clinical-trial timeline on this page — sourced from ClinicalTrials.gov, FDA and SEC filings.